cyrilzakka/clinical-trials huggingface dataset:
Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)

The investigators want to study the relative effects of physical exercise vs. extended-release niacin (lipid-lowering drug) in patients with coronary heart disease and low HDL cholesterol ("good cholesterol") on

* lipid profile
* endothelial function as measured by ultrasound

The endothelium is the inner part of the blood vessels. Impaired endothelial function is known to be associated with atherosclerosis which can ultimately lead to diseases such as stroke, heart attack and others. Endothelial function can be assessed non-invasively by ultrasound.

Both interventions mentioned above have been shown to have a beneficial effect on lipid profile and endothelial function. However, the relative effects are unclear.

Comparison of physical exercise vs. extended-release niacin in patients with CAD and low HDL cholesterol (\< 1,03 mmol/L) on lipid profile and endothelial function as measured by flow-mediated dilatation of radial artery. Secondary goals are the assessment of biochemical markers of atherosclerosis, expression of monocyte surface markers, oxidative stress and thrombogenicity.

Eligibility Criteria:
Inclusion Criteria:

* Coronary disease
* Low HDL cholesterol
* Age limits (see below)

Exclusion Criteria:

* Unstable angina oder MI within 3 months prior to inclusion
* CAD with indication for bypass surgery
* Left main disease ( \> 25% stenosis diameter)
* Ejection fraction \< 40%
* Higher degree heart valve disease
* Higher degree ventricular arrhythmias
* Type 1 Diabetes
* Severe disorders of lipoprotein metabolism (Low-density lipoprotein cholesterol (LDL)\> 5.0 mmol/L)
* Severe liver disease
* Thyroid disease
* Alcohol or drug abuse
* Pregnancy
* Stroke or Transient Ischemic Attack (TIA) within 3 months prior to inclusion
* Allergy against niacin oder other ingredient of niaspan
* Participation in other clinical trial within 30 days prior to inclusion
* Acute gastric ulcer
* Arterial bleeding
* Uncontrolled severe arterial hypertension
* Treatment with lipid-lowering drug other than Hydroxy-Methylglutaryl Coenzyme A (HMG-CoA)-inhibitor within 3 months prior to inclusion
Fat Based Enteral Nutrition for Blood Glucose Control in ICU

In this randomized, double-blind clinical trial, eligible hospitalized ICU patients with EN will be included. Patients will be divided into two groups. The control group with the standard EN and intervention group with high fat EN. 50% of the total fat will be provided by olive oil. Nutritional intake record form will be completed and daily calorie intake will be calculated. High fat EN feeding will be offered for 15 consecutive days maximally. At the end of the study mean blood glucose, duration of hospitalization and rate of infection will be compared in two groups.

In this randomized, double-blind clinical trial, 88 eligible hospitalized ICU patients with EN will be included. Written consent form will be completed. Physical examination will be done by specialist and nutritional care process will be offered by an RD. Demographic, laboratory and nutritional data will be extracted and entered in prepared form. Venous blood samples will be taken and laboratory values will be measured and recorded at specified times. Patients will be divided into two groups. The control group with the standard EN (Protein; 20% carbohydrate; 50% and fat; 30% from total calories) and intervention group with high fat EN (Protein; 20% carbohydrate; 35% and fat; 45% from total calories). 50% of the total fat will be provided by olive oil. Any feeding rout such as naso - gastric , Percutaneous endoscopic gastrostomy (PEG ) or Percutaneous endoscopic jejunostomy (PEJ) with Intermittent feeding protocol will be accepted feeding method . Nutritional intake record form will be completed and daily calorie intake will be calculated. High fat EN feeding will be offered for 15 consecutive days maximally

Eligibility Criteria:
Inclusion Criteria:

* Being on Enteral Nutrition
* BS≥ 200mg/dl
* Without Renal and Liver Failure
* Without Hyperlipidemia and Nephrotic Syndrome
* Without Infection
* Without Obesity

Exclusion Criteria:

* Death or Discharge before Day 7
The De-Morton Mobility Index Turkish Version in Intensive Care Patients

De Morton Mobility Index is recommended for the evaluation of mobility in the evidence-based guidelines, in patients in intensive care units. The aim of our study is to examine the validity and reliability of the Turkish version of the De Morton Mobility Index in patients hospitalized in the respiratory intensive care unit.

De Morton Mobility Index is recommended for the evaluation of mobility in the evidence-based guidelines, in patients in intensive care units. The aim of our study is to examine the validity and reliability of the Turkish version of the De Morton Mobility Index in patients hospitalized in the respiratory intensive care unit.

Patients aged 18 years and over who were discharged from the ICU were included in our study.

We used De-Morton Mobility Index, Bartel Index, Katz Activities of Daily Living Rating Scale and MRC Muscle Strength Test for convergent validity. De-Morton Mobility assessment for test-retest reliability was performed again on the 1st day of the patient's service.

Eligibility Criteria:
Inclusion Criteria:

* staying in intensive care unit for at least 24 hours
* able to cooperate
* being clinically stable for mobility assessment

Exclusion Criteria:

* the presence of neurological disease
* the presence of orthopedic problems such as fractures
* the presence of metastases
* the presence of cardiorespiratory instability
Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis

Upper gastrointestinal hemorrhage (UGIH) is common urgency condition.The estimate mortality rate about 7 percent from peptic ulcers disease(PUD). A proton pump inhibitors (PPIs) intravenous infusion are standard treatment for high risk ulcer bleeding. Vonoprazan,subclass of potassium-competitive acid blockers (P-CABs), have beneficial effects including rapid, long-lasting and strong acid suppression.The investigators design a randomized-controlled trial comparison between 72 hours of intravenous PPIs infusion and oral vonoprazan in high risk ulcer UGIH after achieve endoscopic hemostasis. Outcome measurement are re-bleeding rate in 30 days as primary and re-bleeding rate in 3 days, 30 days mortality, rate of angioembolisation, unit of blood transfusion, hospital cost and length of stay as secondary outcome.


Eligibility Criteria:
Inclusion Criteria:

* High risk peptic ulcers bleeding (Forrest class Ia,Ib,IIa,IIb)

Exclusion Criteria:

* Patients were not achieve endoscopic hemostasis
* End stage cancer disease
* Severe critical illness and ICU setting
* Uncorrectable coagulopathy
* Pregnancy or breast feeding
* Allergy to PPIs or Vonoprazan
Isometric Handgrip Exercise -MRI in Children and Adolescents

This project aims to assess coronary vessel response to isometric handgrip exercise (IHE) during magnetic resonance imaging (MRI) in children with T1D children and healthy controls. The investigators will compare the groups in terms of surrogate markers of intima media alteration and arterial stiffness, i.e. carotid intima media thickness (CIMT) and aortic pulse wave velocity (PWV).

Background Type 1 diabetes mellitus (T1D) in children and adolescents is associated with significant cardiovascular morbidity and mortality. Early detection of vascular dysfunction is key to management yet assessment is invasive - which is particularly challenging when considering pediatric patient populations. Recently, a novel approach using isometric handgrip exercise (IHE) during magnetic resonance imaging (MRI) has been developed to evaluate coronary endothelial function in adults.

This project aims to assess coronary vessel response to IHE using MRI in children with T1D children and healthy controls. In addition, the investigators will compare the groups in terms of surrogate markers of intima media alteration and arterial stiffness, i.e. carotid intima media thickness (CIMT) and aortic pulse wave velocity (PWV).

Community-dwelling healthy volunteers (\<18 years-old) and children with type 1 diabetes mellitus (disease duration ≥ 5 years) are recruited. IHE-MRI studies are conducted and measurements are recorded at rest (baseline) and under stress (IHE at 30% maximal effort). Carotic Ultrasound and Sphygmocor CPV System are used to assess CIMT and PWV respectively. Student's T-tests are used to compare results between groups.

Eligibility Criteria:
Inclusion Criteria:

* Type 1 Diabetes mellitus or
* Healthy community-dwelling children on no medications

Exclusion Criteria:

* smoking
* obesity (BMI \>97th percentile)
* systolic or diastolic hypertension (\>90th percentile)
* inflammatory process.
Intraoperative Radiation Therapy for Locally Advanced or Recurrent Abdomino-pelvic Solid Tumors With the CivaSheet

This study is a pilot study of the CivaSheet, a new type of intraoperative radiation therapy (IORT) device that offers several advantages over existing techniques of performing IORT. The CivaSheet device in this study is already approved by the FDA and is not an experimental device. This study will allow us to determine how feasible it is to implant the CivaSheet into patients undergoing surgery for abdominal and pelvic tumors, and assess any possible side effects of the device. This study, if successful, may allow us to offer the CivaSheet more widely as treatment option to future patients.


Eligibility Criteria:
Inclusion Criteria:

* Histologic, cytologic, or radiologically evidence of locally advanced, residual or recurrent solid malignancy of the abdomen or pelvis requiring surgical resection
* Maximum projected treatment length 15cm and width 5cm, which are the dimensions of the largest available CivaSheet
* Medically fit and willing to undergo resection of disease
* Age ≥ 18 years
* ECOG performance status 0, 1, or 2
* ANC ≥ 1.5 cells/mm3, PLT≥100,000/mm3, PT/aPTT within normal limits at time of surgery
* Life expectancy, in the clinician's judgment, greater than 1 year.

Exclusion Criteria:

* Women who are pregnant
* Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy after the receipt of brachytherapy. Male subjects must also agree to use effective contraception during the treatment period and until 1 year after the completion of brachytherapy
* Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study.
* Patients who, in the investigator's judgment, are unwilling or unable to consent to and return for recommended post-treatment scans as outlined in this study.
* Patients on concurrent anti-cancer therapy, unless specifically agreed to by the patient's medical oncologist and consenting professional.
* Patients with contraindications to general anesthesia, as determined by the treating physician or surgeon
Survey Stroke Units in Argentina

Introduction Patients who receive care from stroke units are more likely to survive their stroke, become independent, and return home. Decision-making to decide the location of discharge is influenced more by non-clinical factors than clinical ones.

Objective To analyze the factors that are considered for discharge and how stroke patients are measured in stroke units in Argentina by the physicians who make the decisions.

Materials and methods An observational, analytical, cross-sectional survey-type study will be carried out. The recommendations given by the Checklist for Reporting of Survey Studies will be used. It will be intended for all those physicians in Argentina who work in stroke units and discharge.


Eligibility Criteria:
Inclusion Criteria:

* All physicians who in stroke units of Argentina and are in charge of the referral process for hospitalized patients will be included.

Exclusion Criteria:

* All surveys with missing data will be excluded
Advancing Interactive Medical Education of Anatomy Via the Metaverse Virtual 3D Printing Platform

The study aims to recruit 100 National Taiwan University 5th grade medical students who have completed a comprehensive basic anatomy course and are just entering surgical clinical rotations. Through a randomized controlled trial, educational training will be designed, and pre- and post-tests will be conducted to compare the effectiveness of learning advanced anatomy using the "Metaverse Virtual 3D Printing System" in virtual reality, versus the traditional method of "using flat diagrams to correlate with computed tomography scans." The study will assess the impact on learning outcomes, motivation, and learning experience in advanced anatomy education. We anticipate a well-structured learning model that bridges the gap between foundational and clinical medical courses.

Anatomy is an important component of medical education, especially during surgical clinical rotations. It is crucial for students to be able to correlate the knowledge from flat anatomical diagrams to medical images and actual three-dimensional structures. However, for students with limited experience, transforming unfamiliar anatomical structures from 2D to 3D can be challenging. In recent years, numerous studies have pointed out the significant benefits of using three-dimensional anatomical models in anatomy education. Furthermore, interactive educational tools have shown even greater advantages.

The metaverse is a collective virtual shared space created by the integration of the internet and the physical world. It offers substantial assistance in virtual reality and interactive learning. While repeatedly using physical 3D printing for different body parts can enhance the understanding of three-dimensional structures, it is costly and time-consuming. Thus, through the collaborative effort of National Taiwan University Hospital department of surgery and Graduate institute of networking and multimedia, National Taiwan University, the "Metaverse Virtual 3D Printing System" has been developed to allow medical students to use wearable devices for immersive learning of detailed, interactive anatomy in a virtual platform.

Eligibility Criteria:
Inclusion Criteria:

* Over 18 years old studying in the Department of Medicine at National Taiwan University
* Completed a full one-year anatomy lecture course and gross anatomy internship in the third year at the Department of Medicine, National Taiwan University.
* Students who have not yet received a complete clinical internship in thoracic surgery.
* Recruit willing subject medical students during their internship in thoracic surgery

Exclusion Criteria:

* Cybersickness
* Person who is sensitive to light stimulation
Comparative Study inTreatment of Trigeminal Neuralgia

This study aims to evaluate the results of percutaneous radiofrequency rhizotomy and the effectiveness of microvascular decompression for the treatment of trigeminal neuralgia and Comparing between them according the different outcome parameters.

This is prospective case -series hospital based study, will be conducted on 40 patients with trigeminal neuralgia treated either by percutaneous radiofrequency trigeminal rhizotomy or microvascular decompression at Sohag University Hospitals, between march 2021 and June 2022 and we will divide the the patients into two groups ,one group will be treated with percutaneous radiofrequency trigeminal rhizotomy and the other group will be treated with microvascular decompression and we will asses the results with the Barrow Neurological Institute Pain Intensity Score .

Eligibility Criteria:
Inclusion Criteria:

* Failed medical treatment more than 6 months

Exclusion Criteria:

* Coagulation disorder or hemorrhagic disease;
* Mental illness and inability to cooperate;
Quality of Vision in Implantable Collamer Lens (ICL)

The aim of this study is to observe the influence of pupil size upon visual outcome in patients with Visian Implantable Collamer Lens(ICL) and toric-ICL implantation.

The aim of this study is to observe the influence of pupil size upon the quality of vision outcome in patients with Visian Implantable Collamer Lens(ICL) and toric-ICL implantation. Pre-operation and 3-month post-operation pupil size, visual acuity, quality of vision will be evaluated in patient that had ICL surgery.

Eligibility Criteria:
Inclusion Criteria:

* Myopic eyes
* Preoperative corneal endothelial cell count ≥2200/mm2
* Preoperative central anterior chamber depth\> 2.80mm
* Intraocular pressure within the normal range (10-21mmHg)

Exclusion Criteria:

* Severe dry eye
* Cataract and glaucoma
* Patients with uveitis
* Retinal detachment
* Patients with autoimmune diseases
* Patients with systemic diseases such as diabetes and hypertension
* Patients with mental or cognitive abnormalities
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

A Phase 1, Single-centre, Double-blind, Placebo controlled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants


Eligibility Criteria:
Inclusion Criteria:

* Male aged 18 to 45 years, inclusive at Visit 1.
* Healthy on the basis of medical history, psychiatric history, physical examination, vital signs, 12-lead electrocardiogram (ECG), haematology, blood chemistry and urinalysis within 6 weeks of Visit 2.
* Right-handed.
* Not a regular smoker (maximum 5 cigarettes per week or equivalent).

Exclusion Criteria:

* History of, or current condition of, migraine headaches or has undergone operations to the head.
* History of significant claustrophobia.
Treatment of Nevus Flammeus With Alexandrite Laser

Nevus flammeus is a congenital vascular malformation. Nevus flammeus is traditionally treated with pulsed dye lasers (PDL); however, around 20 percent of patients are poor responders and do not get satisfactory results from pulsed dye laser treatments.

Small studies with alexandrite lasers indicate that this may be an alternative treatment for individuals with nevus flammeus. This study assesses the clinical effect and side effects of alexandrite laser treatment for nevus flammeus using different treatment settings.


Eligibility Criteria:
Inclusion Criteria:

* 10 or more years of age
* Fitzpatrick Skin Type I-III
* Previously untreated or pulsed dye laser-insufficiently treated nevus flammeus
* Nevus flammeus size minimum 8 x 2 centimeter within one anatomical region
* Written and oral informed consent

Exclusion Criteria:

* Known light sensibility toward visible light
* Tendency to develop hypertrophic scars or keloids
* Fitzpatrick Skin Type IV-VI
* Individuals, that are obviously pigmented due to recent sun exposure or sun beds
* Treatment with systemic retinoids within 6 months
* Pregnancy and lactation
* Unwillingness to complete protocol
Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)

Antiviral treatment on Chronic Hepatitis B (CHB) patients with liver cirrhosis is compulsory and effective. Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral treatment on CHB patients with liver cirrhosis.

Antiviral therapy on CHB patients with liver cirrhosis is compulsory and effective. Diseases development can be prevented or delayed if the virus is depressed successfully. Lamivudine is often used and usually has good efficacy. However, lamivudine resistance and virus mutation happens a lot. Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral treatment on CHB patients with liver cirrhosis.

Eligibility Criteria:
Inclusion Criteria:

* liver cirrhosis with CHB
* without history of antiviral therapy or discontinued antiviral therapy for more than 6 months
* for patients with compensated liver cirrhosis: HBV DNA≥4log copies/ml if HBeAg positive,HBV DNA≥3log copies/ml if HBeAg negative
* for patients with uncompensated liver cirrhosis:HBV DNA positive

Exclusion Criteria:

* coinfection with HCV,HDV and HIV
* AFP≥100mg/L or HCC diagnosed by iconography
* with severe cardiovascular, respiratory and endocrinology diseases or autoimmune diseases
Storytelling Intervention for African Americans Living With Hypertension

Narrative communication (e.g., storytelling) is an approach that has contributed to behavioral change for individuals with conditions such as diabetes, breast cancer, and hypertension. The objective of this study is to conduct a feasibility and pilot study storytelling intervention for African Americans with hypertension. In the feasibility phase 30 African Americans with hypertension will be recruited to view nine patient stories and provide feedback on the effectiveness, usefulness, and satisfaction with the stories. Nine African Americans adults with hypertension were filmed, sharing experiences living with and managing hypertension; including, diet and exercise tips, suggestions for locating healthy foods, and motivational stories about successfully controlling hypertension. During the feasibility phase feedback will also be elicited from the participants about the best approaches for delivering a storytelling intervention, and obtain feedback on the resources and health information that would be helpful to an individual participating in a storytelling intervention. In the pilot study phase, 30 African Americans adults with hypertension will be recruited to participate in a 6-week trial, each week the participants will watch one story and review one module of health information accessible through the study specific website developed for the High Blood Pressure Stories (HBPStories) study. Data will be collected at baseline and 6-weeks including systolic and diastolic blood pressure, medication adherence, health behaviors such as diet and physical activity, and psychosocial measures including positive affect and self-efficacy in the management of hypertension.


Eligibility Criteria:
Inclusion Criteria:

The study inclusion criteria are as follows:

* self-reported hypertension
* race/ethnicity: Black or African American
* prescribed antihypertensive medication
* age ≥ 18 years

Exclusion Criteria:

The exclusion criteria are:

* cognitive limitations that limit the ability to provide informed consent
* unable to speak or read English